NCT07226154 Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
| NCT ID | NCT07226154 |
| Status | Recruiting |
| Phase | — |
| Sponsor | City of Hope Medical Center |
| Condition | Pancreatic Ductal Adenocarcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-11-15 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-11-15 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed pancreatic ductal adenocarcinoma (PDAC). * Underwent neoadjuvant chemotherapy (FOLFIRINOX or Gemcitabine/nab-paclitaxel). * Availability of pre-treatment plasma samples. * Underwent curative-intent resection (R0 or R1). Exclusion Criteria: * Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis. * Non-adenocarcinoma histology. * Presence of synchronous or multiple primary malignancies. * Receipt of chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM-NABP). * Presence of active inflammatory or autoimmune diseases.
Contact & Investigator
Ajay Goel, PhD
PRINCIPAL INVESTIGATOR
City of Hope Medical Center
Frequently Asked Questions
Who can join the NCT07226154 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Ductal Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07226154 currently recruiting?
Yes, NCT07226154 is actively recruiting participants. Contact the research team at ajgoel@coh.org for enrollment information.
Where is the NCT07226154 trial being conducted?
This trial is being conducted at Duarte, United States.
Who is sponsoring the NCT07226154 clinical trial?
NCT07226154 is sponsored by City of Hope Medical Center. The principal investigator is Ajay Goel, PhD at City of Hope Medical Center. The trial plans to enroll 200 participants.